Fezolinetant

Drug Profile

Fezolinetant

Alternative Names: ESN-364

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Euroscreen
  • Developer Ogeda
  • Class Small molecules
  • Mechanism of Action Gonadal steroid hormone modulators; Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hot flashes; Polycystic ovary syndrome; Uterine leiomyoma
  • Phase I Benign prostatic hyperplasia; Endometriosis

Most Recent Events

  • 04 Jan 2017 Efficacy and adverse event data from a phase II trial in Hot flashes, which met its primary endpoint, released by Ogeda
  • 20 Dec 2016 Ogeda has patent protection for fezolinetant in USA
  • 19 Oct 2016 Euroscreen is now called Ogeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top